Securities code: 603122 securities abbreviation: Hefu China Announcement No.: pro 2022019 Hefu (China) Medical Technology Co., Ltd
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
1. The stock price of Hefu (China) Medical Technology Co., Ltd. (hereinafter referred to as “the company”) deviated from the daily closing price by more than 20% in three consecutive trading days on March 17, March 18 and March 21, 2022. The stock price of the company has increased greatly since it was listed, and has touched abnormal fluctuations for five times. The stock trading situation of the company has obviously deviated from the growth range of the same industry and Shanghai stock index. The company specially reminds investors to pay attention to the trading risks in the secondary market.
2. The P / E ratio of the company is much higher than that of the same industry and comparable listed companies. According to the data on the website of China Securities Index Co., Ltd., the static P / E ratio of the company is 132.82 and the rolling P / E ratio of the company is 135.76 as of March 21, 2022. According to the industry data released on the website of China Securities Index Co., Ltd., the static P / E ratio of the wholesale industry of the company is 18.93 and the rolling P / E ratio is 16.54, Investors should pay attention to transaction risks.
The company has disclosed the announcement of abnormal fluctuations in stock trading for three consecutive times on February 22, February 25 and March 2, 2022, the announcement of abnormal fluctuations and risks in stock trading on March 4, and the announcement of risks in stock trading on March 5 and March 11. In view of the large fluctuation of the company’s stock price in the short term, the company hereby reiterates the following on relevant matters and risks. Please make rational decisions and pay attention to investment risks.
1、 Details of stock trading (abnormal) fluctuations
The daily closing price of the company’s stock price deviated by more than 20% in three consecutive trading days on March 17, March 18 and March 21, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to the abnormal fluctuation of stock trading price.
As of the date of this announcement, since the listing of the company’s shares (except the first day), the cumulative increase has reached 345.27%, the cumulative deviation from the Shanghai stock index is 135.19%, and the cumulative turnover rate is 341.66%. The company’s short-term share price has increased greatly. Please pay attention to the trading risk of the secondary market, make rational decisions and pay attention to investment risk.
2、 Relevant information concerned and verified by the company
(I) operation
According to the company’s self inspection, the company’s daily business activities are normal, the market environment and industrial policies have not been significantly adjusted, the production cost and sales have not fluctuated significantly, the internal production and operation order is normal, and the internal and external business environment of the company has not changed significantly.
(II) major events
After self inspection by the company and verification with the controlling shareholder Hefu (Hong Kong) Holding Co., Ltd. (hereinafter referred to as “Hefu Hong Kong”) and the indirect controlling shareholder Cowealth medical Holding Co., Ltd. (hereinafter referred to as “Hefu holding”), as of the disclosure date of this announcement, in addition to the information publicly disclosed on the designated media, There are no major matters affecting the abnormal fluctuation of the company’s stock trading price; There is no other major information that should be disclosed but not disclosed by the company, including but not limited to major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase, equity incentive, bankruptcy restructuring, major business cooperation, introduction of strategic investors and other major matters.
(III) media reports, market rumors and hot concepts
After verification, as of the disclosure date of this announcement, the company has not found any media reports or market rumors and matters involving the concept of hot spots that may or have had an impact on the trading price of the company’s shares.
(IV) other stock price sensitive information
After verification, the company has not found any other major events that may have a great impact on the company’s stock price, and the company’s directors, supervisors, senior managers, controlling shareholders, indirect controlling shareholders and other important shareholders did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that as of the disclosure date of this announcement, the company has no undisclosed matters or planning, negotiation, intention and agreement related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange; The board of directors has not been informed that the company has information that should be disclosed but has not been disclosed in accordance with relevant provisions such as the Listing Rules of Shanghai Stock Exchange, which has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
3、 Relevant risk tips
The company has disclosed the stock trading risk warning announcement on March 11. In view of the continuous rise and limit of the company’s shares in the short term, the company reiterates the following matters and risks. Please make rational decisions and pay attention to investment risks.
1. Risk of high P / E ratio of the company
The P / E ratio of the company is relatively high. According to the data on the website of China Securities Index Co., Ltd., the static P / E ratio of the company is 132.82 and the rolling P / E ratio of the company is 135.76 as of March 21, 2022. According to the industry data released on the website of China Securities Index Co., Ltd., the static P / E ratio of the wholesale industry of the company is 18.93 and the rolling P / E ratio is 16.54. Please pay attention to the transaction risk.
As of March 21, 2022, select listed companies close to the company’s main business for price earnings ratio comparison, as follows:
Serial number securities code securities abbreviation static P / E ratio rolling P / E ratio
1 Shanghai Runda Medical Technology Co.Ltd(603108) . SH Shanghai Runda Medical Technology Co.Ltd(603108) 21.34 16.78
Company 132.82 135.76
Note: the data comes from the website of China Securities Index Co., Ltd
As of March 21, 2022, the company’s rolling P / E ratio is higher than the average value of the above listed companies, while the static P / E ratio is significantly higher than the average value of the above listed companies. Investors should pay attention to transaction risks.
2. Risk of intensified market competition
In recent years, the in vitro diagnosis industry has become one of the rapidly developing fields in China’s medical and health industry. The increasing market demand and the encouragement of national policies will attract more manufacturers to enter, and the market competition will further intensify.
If the company cannot continuously improve its product layout, sales and service network in the future, the fierce market competition environment may have an adverse impact on the company’s production, operation and profitability.
3. Epidemic risk of new pneumonia
As the epidemic situation has not yet fundamentally ended, the epidemic prevention work still needs to be continued. In the future, if China’s New Coronavirus pneumonia epidemic prevention effect can not be sustained or affected by COVID-19 pneumonia outside the country, other downstream medical institutions will concentrate on the treatment of COVID-19 pneumonia patients. In order to avoid cross infection in hospitals, the number of regular visits in hospitals will be reduced, and the consumption of reagents consumed by clinics will be reduced. This will have adverse effects on the company’s performance.
The company solemnly reminds investors that Shanghai Securities News, China Securities News, securities times and Securities Daily are the designated information disclosure newspapers of the company, and the website of Shanghai Stock Exchange (www.sse. Com. CN.) Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please pay attention to investment risks.
It is hereby announced.
Board of directors of Hefu (China) Medical Technology Co., Ltd. March 22, 2022
